The DEA’s marijuana rescheduling hearing continues to raise important questions for cannabis businesses, investors, and the industry as a whole. If you’re trying to keep up with where things stand and what may come next, this upcoming MJBizDaily webinar is worth your time. Harris Sliwoski attorney Jason Adelstone will join a panel of industry professionals
Until last week, federal law prohibited marijuana users from owning or possessing firearms, even in states where marijuana is legal. In recent years, we have covered the differing opinions by federal courts challenging this status quo. On June 18, 2026, the Supreme Court held in a 9-0 decision in U.S. v. Hemani that 18 U.S.C.
On April 28, 2026, Acting Attorney General Blanche (“AG”) issued a notice of hearing concerning the proposed rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). The notice replaced the hearing that began in December 2024 (“2024 Hearing”), which the AG terminated upon issuing the new notice. The
The Washington State Liquor and Cannabis Board (LCB) published an interesting bulletin this Tuesday, June 16th. The bulletin finds that DEA’s final rule on medical marijuana rescheduling “does not appear to apply to Washington’s cannabis licensees, due to the statutory framework predominantly regulating recreational cannabis.” The word “predominantly” is doing a lot of work in
Harris Sliwoski attorney Jason Adelstone will present at the International Cannabis Bar Association’s (INCBA) Cannabis Law Institute 2026, taking place June 17–18 in Chicago and hosted by Northwestern Pritzker School of Law. Jason will join Adi Rozenfeld of Herzog Fox & Neeman and Sahar Ayinehsazian of A.Y. Strauss for a panel discussion titled: Beyond Borders:
With just over two weeks until DEA’s expedited processing deadline for state legal operators to apply for DEA registration, several petitioners litigating the legality of the DEA’s final rule have filed a motion to stay DEA’s final rule in the D.C. Circuit (“Motion”). The Motion was brought by the National Drug and Alcohol Screening Association,
Washington Cannabis Licensing: What Buyers Need to Know We get questions about Washington cannabis licensing all the time. The first question is usually whether new licenses are even available. For most buyers, the answer is no. Washington is a capped market, which means entry usually depends on buying or investing in an existing licensed business.
Chambers and Partners, the London-based legal research and rankings organization, has once again recognized Harris Sliwoski among the leading cannabis law firms in the United States. In its 2026 rankings, Chambers ranked Harris Sliwoski in Band 4 nationally and recognized two of the firm’s cannabis attorneys for their industry-leading work: Vince Sliwoski in Band 3
Minnesota continues to refine its cannabis framework with an Omnibus Cannabis Bill affecting licensed cannabis (marijuana) businesses, hemp operators and medical patients. The new package was signed by Governor Waltz last week. Some of the changes are effective immediately, while others take effect January 1, 2027. It’s common for state cannabis programs to evolve through
On May 22, the states of Nebraska, Indiana, and Louisiana filed a Petition for Review in the United States Court of Appeals for the District of Columbia Circuit (“DC Circuit”) challenging the Acting Attorney General’s (“AG”) final agency action moving FDA-approved and state-licensed marijuana into Schedule III of the Controlled Substances Act (“CSA”). The DC
